Ovarian fibrosis in polyendocrine metabolic ovarian syndrome: emerging mechanisms and therapeutic implications
- 1Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital
Abstract
Polyendocrine metabolic ovarian syndrome (PMOS) remains a leading cause of anovulatory infertility worldwide, traditionally managed through systemic hormonal and metabolic stabilization. However, recent evidence has increasingly identified ovarian fibrosis, which is characterized by excessive extracellular matrix deposition and structural remodeling, as a critical hallmark of reproductive decline in affected individuals. This review provides a comprehensive synthesis of the evolving PMOS landscape, bridging the gap between classic endocrine dysfunction and the newly recognized fibrotic microenvironment. We systematically evaluate the pathogenesis of PMOS, ranging from hyperandrogenemia and insulin resistance to chronic low-grade inflammation, while detailing the molecular drivers of fibrosis such as the TGF-β/CTGF axis and mitochondrial exhaustion. Furthermore, we analyze current therapeutic modalities, including pharmacological agents, regenerative medicine, and traditional Chinese medicine, which highlight a paradigm shift toward precision interventions. Despite these advancements, the precise causal mechanisms linking PMOS to fibrotic pathology remain underexplored, and targeted curative strategies are scarce. We conclude by proposing that alleviating ovarian fibrosis through drug, metabolic, and immunomodulatory pathways represents a high-potential frontier. Future research should prioritize these anti-fibrotic strategies to not only alleviate symptoms but also fundamentally restore ovarian function and extend reproductive longevity.
Related
- Bidirectional regulation of pancreatic stellate cell-mediated pancreatic fibrosis by prostaglandin subtypes: mechanisms and therapeutic implications
- Exerkines in Cardiovascular–Kidney–Metabolic Syndrome: An Integrative Framework for Mechanisms and Therapeutic Implications—A Narrative Review
- Metabolic reprogramming in pulmonary fibrosis: mechanisms and therapeutic perspectives
- Follicular development impairment in polyendocrine metabolic ovarian syndrome: multidimensional pathophysiological networks and frontier therapeutic targets
- Medicine–Food Homology Bioactives for Polyendocrine Metabolic Ovarian Syndrome: Multi-Target Mechanisms and Functional Food Translation
BibTeX
@article{gu2026ovarian,
title = {{Ovarian fibrosis in polyendocrine metabolic ovarian syndrome: emerging mechanisms and therapeutic implications}},
author = {Mengqing Gu and Jing Wang and Zhonghong Zeng and Yang Yu},
journal = {Reproductive Biology and Endocrinology},
year = {2026},
month = jul,
doi = {10.1186/s12958-026-01592-3},
url = {https://doi.org/10.1186/s12958-026-01592-3},
note = {CC BY},
}
RIS
TY - JOUR
TI - Ovarian fibrosis in polyendocrine metabolic ovarian syndrome: emerging mechanisms and therapeutic implications
AU - Mengqing Gu
AU - Jing Wang
AU - Zhonghong Zeng
AU - Yang Yu
PY - 2026
DA - 2026/07/01
JO - Reproductive Biology and Endocrinology
DO - 10.1186/s12958-026-01592-3
UR - https://doi.org/10.1186/s12958-026-01592-3
AB - Polyendocrine metabolic ovarian syndrome (PMOS) remains a leading cause of anovulatory infertility worldwide, traditionally managed through systemic hormonal and metabolic stabilization. However, recent evidence has increasingly identified ovarian fibrosis, which is characterized by excessive extracellular matrix deposition and structural remodeling, as a critical hallmark of reproductive decline in affected individuals. This review provides a comprehensive synthesis of the evolving PMOS landscape, bridging the gap between classic endocrine dysfunction and the newly recognized fibrotic microenvironment. We systematically evaluate the pathogenesis of PMOS, ranging from hyperandrogenemia and insulin resistance to chronic low-grade inflammation, while detailing the molecular drivers of fibrosis such as the TGF-β/CTGF axis and mitochondrial exhaustion. Furthermore, we analyze current therapeutic modalities, including pharmacological agents, regenerative medicine, and traditional Chinese medicine, which highlight a paradigm shift toward precision interventions. Despite these advancements, the precise causal mechanisms linking PMOS to fibrotic pathology remain underexplored, and targeted curative strategies are scarce. We conclude by proposing that alleviating ovarian fibrosis through drug, metabolic, and immunomodulatory pathways represents a high-potential frontier. Future research should prioritize these anti-fibrotic strategies to not only alleviate symptoms but also fundamentally restore ovarian function and extend reproductive longevity.
SN - 1477-7827
ER -